PMID- 31568801
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 157
DP  - 2019 Nov
TI  - Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An 
      evidence-based pharmacoeconomics evaluation.
PG  - 107867
LID - S0168-8227(19)30511-X [pii]
LID - 10.1016/j.diabres.2019.107867 [doi]
AB  - AIM: To evaluate the efficacy, safety and cost-effectiveness of ipragliflozin as 
      an add-on therapy in patients with type 2 diabetes mellitus (T2DM). METHODS: 
      PubMed, EMBASE, the Cochrane Library, Web of Science and four Chinese databases, 
      as well as the ClinicalTrials.gov website were searched from their inception 
      through Jan 2019. Methodological quality was assessed using the Cochrane risk of 
      bias, and meta-analysis was performed using RevMan5.3. RESULTS: A total of 11 
      randomized controlled trials with 1766 patients were included. Ipragliflozin 
      administered (50 mg) once daily as an add-on therapy to other glucose-lowering 
      medications (metformin, pioglitazone, sulfonylurea, alpha-glucosidase inhibitor, 
      sitagliptin, insulin) was associated with reductions in hemoglobin A1c (HbA1c) of 
      -0.74% (95% confidence interval (CI) -1.00 to -0.48), fasting plasma glucose (WMD 
      -25.03 mg/dL; 95% CI -32.89 to -17.16), weight, waist circumference, blood 
      pressure, and triglycerides levels. Neither the incidence of treatment-emergent 
      adverse events (TEAEs) (RR 1.08; 95% CI 1.00 to 1.16) nor drug-related TEAEs (RR 
      1.19; 95% CI 0.93 to 1.54) was significantly increased. However, it was 
      associated with an increased risk of hypoglycemia when added to insulin (RR 1.71; 
      95% CI 1.13 to 2.61). Compared with the pioglitazone group and the 
      sitagliptin + metformin group, the incremental cost-effectiveness ratio of 
      ipragliflozin add-on therapy group was $4976.89, $2089.76 per percentage of 
      qualified HbA1c, respectively. CONCLUSION: Ipragliflozin as an add-on therapy is 
      well tolerated and effective. Ipragliflozin as an add-on therapy do not appear 
      cost-effective compared with metformin alone, but may be competitive against 
      pioglitazone group and the sitagliptin + metformin group.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Wang, Hongmei
AU  - Wang H
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Yao, Gaoqiong
AU  - Yao G
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Chen, Xi
AU  - Chen X
AD  - Department of Pharmacy, Hebei University of Science and Technology, Hebei, China.
FAU - Ouyang, Jing
AU  - Ouyang J
AD  - Department of Pharmacy, Chongqing Public Health Medical Center, Chongqing, China. 
      Electronic address: ouyangjing820421@126.com.
FAU - Yang, Jiadan
AU  - Yang J
AD  - Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China. Electronic address: yangjiadan11@126.com.
LA  - eng
PT  - Journal Article
DEP - 20190927
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiophenes)
RN  - 3N2N8OOR7X (ipragliflozin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination/*methods
MH  - Economics, Pharmaceutical/*standards
MH  - Female
MH  - Glucosides/pharmacology/*therapeutic use
MH  - Glycated Hemoglobin/drug effects
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Middle Aged
MH  - Sodium-Glucose Transporter 2 Inhibitors/pharmacology/*therapeutic use
MH  - Thiophenes/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Add-on therapy
OT  - Cost-effectiveness analysis
OT  - Ipragliflozin
OT  - Meta-analysis
OT  - Type 2 diabetes mellitus
EDAT- 2019/10/01 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/10/01 06:00
PHST- 2019/04/13 00:00 [received]
PHST- 2019/09/08 00:00 [revised]
PHST- 2019/09/23 00:00 [accepted]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/10/01 06:00 [entrez]
AID - S0168-8227(19)30511-X [pii]
AID - 10.1016/j.diabres.2019.107867 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2019 Nov;157:107867. doi: 10.1016/j.diabres.2019.107867. 
      Epub 2019 Sep 27.